Table 2.
Treatment results of the s-IVB, m-IVB and PDT groups at three months after treatment
| s-IVB group | m-IVB group | PDT group | P value | |
|---|---|---|---|---|
| BCVA (logMAR) | 0.55±0.37 | 0.47±0.37 | 0.45±0.34 | 0.553 |
| Improvement of BCVA (>0.2) | Two out of 18 eyes | Three eyes (14%) | 15 eyes (31%) | 0.124 |
| Foveal thickness (μm) | 353.3±162.3 | 331.5±194.0 | 269.9±157.8 | 0.133 |
| Improvement of foveal thickness (>0.20%) | Six out of 18 eyes | 10 eyes (46%) | 35 eyes (71%) | 0.009 |
| Resolution of polyps | Three out of 18 eyes | One eye (5%) | 35 eyes (71%) | <0.001 |
s-IVB: Single intravitreal bevacizumab, m-IVB: Monthly intravitreal bevacizumab, PDT: Photodynamic therapy, BCVA: Best-corrected visual acuity